7,675 results match your criteria Clinical Safety in Neurology


Discontinuation of antibiotics in patients with Neurological Conditions - A Study on the Impact of Antimicrobial Stewardship Program (ASP) in a Tertiary Institution.

Int J Antimicrob Agents 2020 May 29:106038. Epub 2020 May 29.

Department of Pharmacy, Singapore General Hospital, Outram Road, Singapore 169608, Singapore; Emerging Infectious Diseases, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore; Singhealth Duke-NUS Medicine Academic Clinical Programme, Singapore. Electronic address:

Background: In most hospitals worldwide, 30% to 50% of antibiotics are prescribed either unnecessarily or inappropriately. In the largest tertiary hospital in Singapore, we observed that patients with neurological conditions were often initiated on antibiotics for change in mental state or isolated fevers. We hypothesize that Antimicrobial Stewardship Program (ASP) interventions to discontinue empiric antibiotics in neurological patients with no clinical evidence of bacterial infection is safe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijantimicag.2020.106038DOI Listing

Temperature Measurements in the Vicinity of Human Intracranial EEG Electrodes Exposed to Body-Coil RF for MRI at 1.5T.

Front Neurosci 2020 12;14:429. Epub 2020 May 12.

Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, United Kingdom.

The application of intracranial electroencephalography (icEEG) recording during functional magnetic resonance imaging (icEEG-fMRI) has allowed the study of the hemodynamic correlates of epileptic activity and of the neurophysiological basis of the blood oxygen level-dependent (BOLD) signal. However, the applicability of this technique is affected by data quality issues such as signal drop out in the vicinity of the implanted electrodes. In our center we have limited the technique to a quadrature head transmit and receive RF coil following the results of a safety evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fnins.2020.00429DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235361PMC

Hyperbaric oxygen therapy for post-stroke depression: A systematic review and meta-analysis.

Clin Neurol Neurosurg 2020 May 16;195:105910. Epub 2020 May 16.

Department of Neurology, Tongchuan City People's Hospital, Shanxi 727000, China. Electronic address:

Objectives: Post-stroke depression (PSD) is common consequence of stroke. However, today the majority of PSD patients remains untreated or inadequately treated, especially in the developing countries. Herein, we performed a meta-analysis to evaluate efficacy and safety of hyperbaric oxygen (HBOT) therapy for PSD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2020.105910DOI Listing

Remote ischemic conditioning combined with intravenous thrombolysis for acute ischemic stroke.

Ann Clin Transl Neurol 2020 May 29. Epub 2020 May 29.

Department of Neurology, Stroke Center, The First Hospital of Jilin University, Chang Chun, Jilin, 130021, China.

Objective: The objective of this study was to investigate the safety and efficacy of remote ischemic conditioning (RIC) combined with intravenous thrombolysis (IVT) in the treatment of acute ischemic stroke (AIS).

Methods: Patients with AIS who underwent IVT were enrolled and 1:1 randomized to the RIC group and sham-RIC group in this study. RIC (or sham-RIC) was performed twice within 6-24 h of IVT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acn3.51063DOI Listing

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.

J Allergy Clin Immunol 2020 May 26. Epub 2020 May 26.

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan, Hubei 430030, China;; Clincal Trial and Research Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;. Electronic address:

Background: Accumulating evidence proposed JAK inhibitors as therapeutic targets warranting rapid investigation.

Objective: This study evaluated the efficacy and safety of ruxolitinib, a Janus-associated kinase (JAK1/2) inhibitor, for COVID-19.

Methods: We conducted a prospective, multicenter, single-blind, randomized controlled phase II trial involving patients with severe COVID-19. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2020.05.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250105PMC

Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study.

Lancet Neurol 2020 Jun 26;19(6):491-501. Epub 2020 May 26.

Department of Neurosurgery, University of California, San Francisco, San Francisco, CA, USA.

Background: Deep brain stimulation (DBS) of the subthalamic nucleus is an established therapeutic option for managing motor symptoms of Parkinson's disease. We conducted a double-blind, sham-controlled, randomised controlled trial to assess subthalamic nucleus DBS, with a novel multiple independent contact current-controlled (MICC) device, in patients with Parkinson's disease.

Methods: This trial took place at 23 implanting centres in the USA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(20)30108-3DOI Listing

Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease.

Ann Neurol 2020 May 28. Epub 2020 May 28.

Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA.

Objective: Preclinical evidence with nilotinib, a US Food and Drug Administration (FDA)-approved drug for leukemia, indicates improvement in Alzheimer's disease phenotypes. We investigated whether nilotinib is safe, and detectable in cerebrospinal fluid, and alters biomarkers and clinical decline in Alzheimer's disease.

Methods: This single-center, phase 2, randomized, double-blind, placebo-controlled study investigated the safety, tolerability, and pharmacokinetics of nilotinib, and measured biomarkers in participants with mild to moderate dementia due to Alzheimer's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.25775DOI Listing

Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: the first multicentre, phase III trial in China.

Stroke Vasc Neurol 2020 May 28. Epub 2020 May 28.

Department of Neurology, Beijing Tiantan Hospital, Affiliated Capital Medical University, Beijing, China

Background And Purpose: Data on the efficacy and safety of alteplase for acute ischaemic stroke (AIS) administered 3-4.5 hours after the onset of stroke symptoms in Chinese patients is limited. We sought to determine whether AIS patients would benefit from thrombolysis with alteplase between 3 and 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/svn-2020-000337DOI Listing

Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding.

J Neurol Sci 2020 Apr 29;415:116869. Epub 2020 Apr 29.

Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.

Background And Purpose: Several studies have indicated that altered serotonergic neurotransmission may contribute to the motor features commonly associated with Parkinson's disease (PD) drug treatment such as levodopa-induced dyskinesias (LIDs). 5-Hydroxytryptophan (5-HTP) is the immediate precursor of serotonin. We have recently demonstrated that 5-HTP produces significant antidyskinetic effects in a rat model of PD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2020.116869DOI Listing

Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical Trial.

JAMA Netw Open 2020 May 1;3(5):e206027. Epub 2020 May 1.

Department of Psychiatry, University Hospital Cologne, Medical Faculty, Cologne, Germany.

Importance: Apathy is a frequent neuropsychiatric symptom in dementia of Alzheimer type and negatively affects the disease course and patients' and caregivers' quality of life. Effective treatment options are needed.

Objective: To examine the efficacy and safety of the dopamine and noradrenaline reuptake inhibitor bupropion in the treatment of apathy in patients with dementia of Alzheimer type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamanetworkopen.2020.6027DOI Listing

Low-Frequency Repetitive Transcranial Magnetic Stimulation for the Treatment of Chronic Tinnitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Biomed Res Int 2020 2;2020:3141278. Epub 2020 May 2.

Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, China.

Background: Chronic tinnitus affects approximately 10-15% of the population. Low-frequency repetitive transcranial magnetic stimulation (rTMS) has been considered as a promising and well-tolerated therapeutic strategy for chronic tinnitus. However, a recent large-scale multicenter clinical trial showed a negative result. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/3141278DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218966PMC

Superior accuracy and precision of SEEG electrode insertion with frame-based vs. frameless stereotaxy methods.

Acta Neurochir (Wien) 2020 May 26. Epub 2020 May 26.

Department of Neurosurgery, University of California Davis School of Medicine, 4860 Y St. Suite 3740, Sacramento, 95817, USA.

Background: Stereotactic electroencephalography (SEEG) has largely become the preferred method for intracranial seizure localization in epileptic patients due to its low morbidity and minimally invasive approach. While robotic placement is gaining popularity, many centers continue to use manual frame-based and frameless methods for electrode insertion. However, it is unclear how these methods compare in regard to accuracy, precision, and safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00701-020-04427-1DOI Listing

Transcirculation Approach for Mechanical Thrombectomy in Acute Ischemic Stroke: A Multicenter Study and Review of the Literature.

Front Neurol 2020 7;11:347. Epub 2020 May 7.

Departments of Neurology, Neurosurgery and Radiology, University of Iowa Hospitals and Clinics, Iowa City, IA, United States.

Transcirculation approaches, which consist of primary catheterization of a target artery from the contralateral side or opposite cerebral circulation, provide alternate endovascular routes when anterograde interventions are not feasible. We aimed to assess the safety and efficacy of mechanical thrombectomy (MT) through a transcirculation route. Six centers provided retrospective data on acute ischemic stroke (AIS) patients who underwent MT via transcirculation approaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2020.00347DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221059PMC

Neuroprotective Effects of D-(-)-Quinic Acid on Aluminum Chloride-Induced Dementia in Rats.

Evid Based Complement Alternat Med 2020 11;2020:5602597. Epub 2020 May 11.

Department of Neurology, Baoding No. 1 Central Hospital, Baoding, Hebei 071000, China.

Objective: The present study was designed to evaluate the neuroprotective effects of D-(-)-quinic acid on aluminum chloride- (AlCl-) induced neurobehavioral and biochemical changes in rats. This study showed the behavioral and biochemical effects of D-(-)-quinic acid on rats with particular emphasis on the hippocampus and frontal cortex which are associated with memory.

Materials And Methods: Chronic administration of aluminum chloride at a dose of 175 mg/kg, p. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/5602597DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240662PMC

Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.

JAMA Neurol 2020 May 26. Epub 2020 May 26.

AGADA BioSciences, Dalhousie University, Halifax, Nova Scotia, Canada.

Importance: An unmet need remains for safe and efficacious treatments for Duchenne muscular dystrophy (DMD). To date, there are limited agents available that address the underlying cause of the disease.

Objective: To evaluate the safety, tolerability, and efficacy of viltolarsen, a novel antisense oligonucleotide, in participants with DMD amenable to exon 53 skipping. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaneurol.2020.1264DOI Listing

Augmented Reality-Based Rehabilitation of Gait Impairments: Case Report.

JMIR Mhealth Uhealth 2020 May 26;8(5):e17804. Epub 2020 May 26.

Division of Vascular Neurology and Neurorehabilitation, Department of Neurology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.

Background: Gait and balance impairments are common in neurological diseases, including stroke, and negatively affect patients' quality of life. Improving balance and gait are among the main goals of rehabilitation. Rehabilitation is mainly performed in clinics, which lack context specificity; therefore, training in the patient's home environment is preferable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2196/17804DOI Listing

Longitudinal study of prevalence and spatio-temporal distribution of Borrelia burgdorferi sensu lato in ticks from three defined habitats in Latvia, 1999-2010.

Environ Microbiol 2020 May 25. Epub 2020 May 25.

Bavarian Health and Food Safety Authority, German National Reference Centre for Borrelia, Veterinärstr. 2, 85764 Oberschleissheim, Germany.

Members of the Borrelia (B) burgdorferi sensu lato (s.l.) species complex are known to cause human Lyme borreliosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1462-2920.15100DOI Listing

Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.

J Neurol 2020 May 25. Epub 2020 May 25.

Biogen, Cambridge, MA, USA.

Objective: SELECTED, an open-label extension study, evaluated daclizumab beta treatment for up to 6 years in participants with relapsing multiple sclerosis who completed the randomized SELECT/SELECTION studies. We report final results of SELECTED.

Methods: Eligible participants who completed 1-2 years of daclizumab beta treatment in SELECT/SELECTION received daclizumab beta 150 mg subcutaneously every 4 weeks for up to 6 years in SELECTED. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-020-09835-yDOI Listing

Impact of the COVID-19 pandemic on the process and outcome of thrombectomy for acute ischemic stroke.

J Neurointerv Surg 2020 May 25. Epub 2020 May 25.

Department of Neurosurgery, Xuanwu Hospital, Beijing, China

Background: The novel coronavirus disease 2019 (COVID-19) pandemic is still spreading across the world. Although the pandemic has an all-round impact on medical work, the degree of its impact on endovascular thrombectomy (EVT) for patients with acute ischemic stroke (AIS) is unclear.

Methods: We continuously included AIS patients with large artery occlusion who underwent EVT in a comprehensive stroke center before and during the Wuhan shutdown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/neurintsurg-2020-016177DOI Listing

Nutritional challenges in children and adolescents with Down syndrome.

Lancet Child Adolesc Health 2020 Jun;4(6):455-464

Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. Electronic address:

Several features and comorbidities in Down syndrome have nutritional implications and consequences. In infancy and early childhood, children with Down syndrome have a high risk of oral motor difficulties and pharyngeal dysphagia with aspiration, which both require systematic attention. To improve nutritional status in children who are underweight and who have clinical signs of feeding problems, further evaluation of underlying causes is required. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-4642(19)30400-6DOI Listing

Agreement of Minimum Data Set 3.0 depression and behavioral symptoms with clinical diagnosis in a nursing home.

Aging Ment Health 2020 May 25:1-6. Epub 2020 May 25.

Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA.

While the Minimum Data Set (MDS) 3.0 has adopted Patient Health Questionnaire (PHQ)-9 to screen for depression and rephrased language for behavioral symptoms among nursing home residents, it remains unclear how well the assessment data agree with medical records. Using a retrospective review of MDS 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13607863.2020.1758921DOI Listing

Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.

Drug Saf 2020 May 23. Epub 2020 May 23.

New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ, USA.

Introduction: Although use of contraception was pre-specified during cladribine clinical trials for multiple sclerosis, some pregnancies did occur.

Objective: This analysis reports on pregnancy outcomes in the cladribine clinical development program.

Methods: Pregnancy outcomes in female patients (direct pregnancies) and those arising from partner pregnancies (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40264-020-00948-xDOI Listing

The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a "real world" context: focus on temporal lobe epilepsy.

J Neurol Sci 2020 May 15;415:116903. Epub 2020 May 15.

Institute of Neurology, University "Magna Graecia", Catanzaro, Italy. Electronic address:

Background: Perampanel (PER) is a novel antiepileptic drug approved as an add-on therapy for focal onset seizures with or without generalization and primary generalized tonic-clonic seizures. Aim of this study was to evaluate PER efficacy and tolerability as add-on therapy in patients with drug-resistant focal onset seizures and especially temporal lobe epilepsy (TLE).

Methods: An observational, prospective, multicentre study on adult with drug-resistant focal epilepsy consecutively recruited from six Italian tertiary epilepsy centres. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2020.116903DOI Listing

Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.

Parkinsonism Relat Disord 2020 May 4;75:17-23. Epub 2020 May 4.

Department of Neurology and Clinical Pharmacology, Graduate School of Medicine, Ehime University, Shizugawa, Tohon, Ehime, 791-0295, Japan; Saiseikai Imabari Center for Health and Welfare, 7-6-1 Kitamura, Imabari, Ehime, 799-1592, Japan. Electronic address:

Introduction: Safinamide is a reversible and selective monoamine oxidase-B (MAO-B) and sodium channel inhibitor with demonstrated efficacy in mid-to late-stage Parkinson's disease (PD) as an adjunct to l-DOPA. This study aimed to confirm the efficacy and safety of safinamide in PD patients with wearing-off.

Methods: This 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study included Japanese PD patients with wearing-off on l-DOPA treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2020.04.012DOI Listing

Drug-Coated Balloon Dilation Compared With Conventional Stenting Angioplasty for Intracranial Atherosclerotic Disease.

Neurosurgery 2020 May 23. Epub 2020 May 23.

Department of Neurology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.

Background: Conventional stent-based angioplasty was challenged for the high incidence of perioperative complications and follow-up in-stent restenosis (ISR) in treating intracranial atherosclerotic disease (ICAD). Currently, the drug-coated balloon (DCB) has shown promise in preventing and treating ISR.

Objective: To compare the efficacy and safety of DCB dilation (with or without stenting) with conventionally only stenting angioplasty for symptomatic ICAD in routine clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuros/nyaa191DOI Listing

Efficacy of Levetiracetam in the Treatment of Sydenham Chorea.

Pediatr Int 2020 May 23. Epub 2020 May 23.

Division of Pediatric Neurology, Faculty of Medicine, Mersin University, Mersin, Turkey.

Background: To study the effect of levetiracetam in Sydenham chorea.

Methods: We retrospectively collected the data of 140 patients diagnosed with Sydenham chorea in the pediatric neurology and pediatric cardiology outpatient clinics of Van Training and Research Hospital between January 2010 and December 2018.

Results: There were 140 patients, 102 (70%) girls, with mean age of onset 11. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ped.14318DOI Listing

Amyotrophic Lateral Sclerosis Care and Research in the USA During the COVID-19 Pandemic: Challenges and Opportunities.

Muscle Nerve 2020 May 23. Epub 2020 May 23.

Department of Neurology, Duke University, Durham, NC.

COVID-19 has created unprecedented challenges for amyotrophic lateral sclerosis (ALS) clinical care and research in the United States. Traditional evaluations for making an ALS diagnosis, measuring progression, and planning interventions rely on in-person visits that may now be unsafe or impossible. Evidence- and experience-based treatment options such as multidisciplinary team care, feeding tubes, wheelchairs, home health and hospice have become more difficult to obtain and in some places are unavailable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mus.26989DOI Listing
May 2020
2.283 Impact Factor

An investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke (ECASIS).

Medicine (Baltimore) 2020 May;99(20):e20307

Internal Medicine Department, Hamad General Hospital.

Introduction: Uncertainty remains regarding the impact of enteric-coated (EC) aspirin as it relates to the reduction of cardiovascular risk. We hypothesize that EC formulation based on a previous report may blunt aspirin response as evidenced by reduced Thromboxane A2 (TXA 2) levels in diabetic patients. Thus, it was imperative to ascertain and validate the effect of the EC formulation of Aspirin on the Thromboxane B2 (TXB2) level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020307DOI Listing

Validation of the Safer Opioid Prescribing Evaluation Tool (SOPET) for Assessing Adherence to the Centers for Disease Control Opioid Prescribing Guidelines.

Pain Med 2020 May 22. Epub 2020 May 22.

Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Objective: In response to the opioid epidemic, the Centers for Disease Control and Prevention issued guidelines (CDCG) in 2016 for the prescription of opioids for chronic pain. To facilitate research into whether CDCG implementation will lead to reductions in opioid prescribing and improved patient safety, we sought to validate a tool that quantifies CDCG adherence based on clinical documentation.

Design: The Safe Opioid Prescribing Evaluation Tool (SOPET) was developed in four phases as part of a study to improve the implementation of the CDCG in the clinical setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/pm/pnaa138DOI Listing

Antioxidative effects of a novel dietary supplement Neumentix in a mouse stroke model.

J Stroke Cerebrovasc Dis 2020 May 18:104818. Epub 2020 May 18.

Departments of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Dentistry and Pharmacy, 2-5-1 Shikata-cho, Okayama Okayama Japan. Electronic address:

Background: During an acute stroke, reactive oxygen species are overproduced and the endogenous antioxidative defense systems are disrupted. Therefore, antioxidative therapy can be a promising scheme to reduce the severity of stroke. Neumentix is a novel antioxidative supplement produced from a patented mint line and contains a high content of rosmarinic acid (RA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2020.104818DOI Listing

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.

JAMA Oncol 2020 May 21. Epub 2020 May 21.

Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.

Importance: Clinical outcomes for glioblastoma remain poor. Treatment with immune checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from a randomized phase 3 clinical trial evaluating a programmed death-1 (PD-1) inhibitor therapy for glioblastoma have not been reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2020.1024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243167PMC

Clinical Implementation of Transcranial Direct Current Stimulation in Aphasia: A Survey of Speech-Language Pathologists.

Am J Speech Lang Pathol 2020 May 20:1-13. Epub 2020 May 20.

Department of Communication Sciences and Disorders, University of South Carolina, Columbia.

Purpose The objectives of this study are to (a) identify speech-language pathologists' (SLPs') familiarity with transcranial direct current stimulation (tDCS), (b) quantify what SLPs consider necessary tDCS-related improvement in aphasia severity (i.e., tDCS enhancement; desired improvement above and beyond traditional behavioral therapy) to implement this adjuvant therapy for the clinical management of aphasia, and (c) identify concerns that could potentially hinder the clinical adoption of tDCS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1044/2020_AJSLP-19-00037DOI Listing

Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?

Headache 2020 Jun 21;60(6):1056-1065. Epub 2020 May 21.

Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Objective: To narratively review the pathophysiological rationale of dual therapy with anti-calcitonin gene-related peptide monoclonal antibodies and botulinum toxin type A in treatment-resistant chronic migraine prevention.

Background: For the prevention of chronic migraine, several pharmacological therapies are available, including oral medications, botulinum toxin type A, and the newly approved monoclonal antibodies targeting calcitonin gene-related peptide or its receptor. However, monotherapy does not yield benefits in some affected individuals, which raises the question of whether dual therapy with monoclonal antibodies and botulinum toxin type A hold promise in patients with treatment-resistant chronic migraine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/head.13843DOI Listing

12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (II).

Rev Neurol 2020 Jun;70(11):417-429

Hospital de Cruces, Baracaldo, España.

Introduction: Like every year, after the ECTRIMS Congress, renowned Spanish neurologists who are experts in multiple sclerosis presented the main novelties in research in this field at the Post-ECTRIMS Meeting.

Aim: To summarise the content presented at the 12th edition of the Post-ECTRIMS Meeting, which took place in September 2019 in Sevilla and is presented in two parts.

Development: In this second part, the most recent evidence on the use of disease-modifying treatments during pregnancy is presented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.33588/rn.7011.2020122DOI Listing

A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma.

Invest New Drugs 2020 May 20. Epub 2020 May 20.

Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.

Background PF-06840003 is a highly selective indoleamine 2, 3-dioxygenase (IDO1) inhibitor with antitumor effects in preclinical models. This first-in-human phase 1 study evaluated safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy in recurrent malignant glioma to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). Methods Patients (N = 17) received oral PF-06840003 in four dose-escalation groups: 125 mg once-daily (QD; n = 2); 250 mg QD (n = 4); 250 mg twice-daily (BID; n = 3); 500 mg BID (n = 8). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-020-00950-1DOI Listing

Result of awake surgery for pediatric eloquent brain area tumors: single-center experience.

Childs Nerv Syst 2020 May 21. Epub 2020 May 21.

Psychological Service, Republican Research and Clinical Center of Neurology and Neurosurgery, Minsk, Belarus.

Purpose: About half of brain tumors are located in supratentorial regions and 20% of them in eloquent brain cortex areas. The use of fMRI and intraoperative neuromonitoring allows safe surgery of these areas. Carrying out awake brain surgery (ABS) operations provides additional opportunities for direct-function monitoring. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00381-020-04666-8DOI Listing

Over the Horizon: The Present and Future of Endovascular Neural Recording and Stimulation.

Front Neurosci 2020 6;14:432. Epub 2020 May 6.

Department of Neurology, UTHealth McGovern Medical School, Houston, TX, United States.

The past decade has witnessed an explosion in applications for neural recording and stimulation in the treatment of clinical disorders. Neuromodulatory approaches are now a mainstay of care for essential tremor and Parkinson's disease, and are expanding rapidly into a wide range of other neurological and psychiatric diseases. In parallel, advancements in endovascular approaches to cerebrovascular diseases have resulted in minimally invasive techniques that deliver devices to neural tissue in the central and peripheral nervous systems, with significantly improved safety and efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fnins.2020.00432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218134PMC

Safety of potential breast milk exposure to IFN-β or glatiramer acetate: One-year infant outcomes.

Neurol Neuroimmunol Neuroinflamm 2020 Jul 20;7(4). Epub 2020 May 20.

From the Department of Neurology (A.I.C., S.T., R.G., K.H.), St. Josef Hospital, Ruhr-University Bochum; Institute of Clinical Pharmacy and Pharmacotherapy (A.I.C.), Heinrich-Heine-University, Dusseldorf, Germany; Department of Neurology (A.L.-G.), Southern California Permanente Medical Group/Kaiser Permanente, Los Angeles Medical Center; Department of Paediatrics (A.S.), St. Josef Hospital, Ruhr-University Bochum; and Centre of Paediatrics and Youth Medicine (A.Q.-W.), Johannes Gutenberg University of Mainz, Germany.

Objective: To determine whether potential breast milk exposure to interferon-beta (IFN-β) or glatiramer acetate (GA) is safe for the infant.

Methods: We identified 74 infants born to 69 women with MS who breastfed under IFN-β (n = 39), GA (n = 34), or both (n = 1). Women had been enrolled into the German Multiple Sclerosis and Pregnancy Registry during pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000757DOI Listing

Thrombectomy Technique Predicts Outcome in Posterior Circulation Stroke-Insights from the STAR Collaboration.

Neurosurgery 2020 May 20. Epub 2020 May 20.

Department of Neurosurgery, Medical University of South Carolina, Charleston, South Carolina.

Background: Randomized controlled trials evaluating mechanical thrombectomy (MT) for acute ischemic stroke predominantly studied anterior circulation patients. Both procedural and clinical predictors of outcome in posterior circulation patients have not been evaluated in large cohort studies.

Objective: To investigate technical and clinical predictors of functional independence after posterior circulation MT while comparing different frontline thrombectomy techniques. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuros/nyaa179DOI Listing
May 2020
3.620 Impact Factor

Infarct in new territory after endovascular stroke treatment: A diffusion-weighted imaging study.

Sci Rep 2020 May 20;10(1):8366. Epub 2020 May 20.

Department of Neurology, University Hospital Bern, Inselspital, University of Bern, Bern, Switzerland.

Data on infarcts in new territory (INT) in patients undergoing endovascular stroke treatment for acute large-vessel occlusions are sparse. Aim of this study was to assess the prevalence, risk factors, and clinical relevance of INT. For this purpose, all patients in a single-center prospective registry who underwent endovascular stroke treatment and received pre- and post-interventional diffusion-weighted imaging were included (N = 259). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-64495-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239894PMC

Improving Stroke Care in Times of the COVID-19 Pandemic Through Simulation: Practice Your Protocols!

Stroke 2020 May 20:STROKEAHA120030091. Epub 2020 May 20.

Department of Clinical Neurosciences, University of Calgary, AB, Canada. (J.M.O., M.G.).

During the coronavirus disease 2019 (COVID-19) pandemic, infectious disease control is of utmost importance in acute stroke treatment. This is a new situation for most stroke teams that often leads to uncertainty among physicians, nurses, and technicians who are in immediate contact with patients. The situation is made even more complicated by numerous new regulations and protocols that are released in rapid succession. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/STROKEAHA.120.030091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7258763PMC

Dietary interventions for multiple sclerosis-related outcomes.

Cochrane Database Syst Rev 2020 May 19;5:CD004192. Epub 2020 May 19.

Department of Nutrition, Texas A&M University, College Station, Texas, USA.

Background: Multiple sclerosis (MS) is a common demyelinating disease of the central nervous system. Although the exact pathogenesis remains unknown, the leading theory is that it results from immune system dysregulation. Approved disease-modifying therapy appears to modulate the immune system to improve MS-related outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD004192.pub4DOI Listing

Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials.

Ther Adv Neurol Disord 2020 28;13:1756286420918088. Epub 2020 Apr 28.

First Neurology Department, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens, 74 V. Sofia's Avenue, Athens 11528, Greece.

Background: Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares data also for the prophylaxis of cluster headache.

Objective: To provide a pooled safety and efficacy analysis of all phase III randomized controlled trials of galcanezumab in the preventive therapy of migraine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756286420918088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222235PMC

Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE.

Ther Adv Neurol Disord 2020 12;13:1756286420915005. Epub 2020 May 12.

Biogen, 225 Binney Street, Cambridge, MA 02142, USA.

Introduction: We report safety and efficacy in patients treated with dimethyl fumarate (DMF) for ~9 years in ENDORSE. Lymphocyte analysis data are also reported.

Methods: Incidence of serious adverse events (SAEs), discontinuations due to adverse events (AEs), annualized relapse rate (ARR) and Expanded Disability Status Scale (EDSS) score were assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756286420915005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222239PMC

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study.

Ther Adv Neurol Disord 2020 6;13:1756286420911784. Epub 2020 May 6.

Department of Neurology, University of North Carolina, Chapel Hill, NC, USA.

Background: In the phase III eculizumab for refractory generalized myasthenia gravis REGAIN study [ClinicalTrials.gov identifier: NCT01997229] and its open-label extension (OLE) [ClinicalTrials.gov identifier: NCT02301624], patients with treatment-refractory antiacetylcholine receptor antibody-positive generalized myasthenia gravis had clinically meaningful improvements with eculizumab placebo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756286420911784DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222230PMC

Low Incidence of Maternal Near-Miss in Zhejiang, a Developed Chinese Province: A Cross-Sectional Study Using the WHO Approach.

Clin Epidemiol 2020 29;12:405-414. Epub 2020 Apr 29.

Department of Obstetrics and Gynaecology, Women's Hospital, Zhejiang University School of Medicine, People's Republic of China.

Background And Aim: Maternal near-miss (MNM) surveillance has been developed to identify severe complications in pregnancy since 2011 in China. However, very little is known about MNM in China. This study aims to explore the prevalence of MNM, the risk factors, and perinatal outcomes using the WHO near-miss approach in a developed Chinese province. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CLEP.S243414DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196796PMC

Gene therapy for Parkinson's disease: contemporary practice and emerging concepts.

Expert Rev Neurother 2020 May 19:1-14. Epub 2020 May 19.

Department of Neurological Surgery, College of Medicine, The Ohio State University, Columbus, OH, USA.

: Gene therapy is a rapidly evolving technology that has predominantly utilized viral vectors to effectively deliver genetic material inside neurons to modulate the expression of one or more particular genes. Several gene therapy clinical trials have been conducted in Parkinson's disease (PD) by exploring strategies to either restore dopamine synthesis, enhance the production of trophic factors, enhance lysosomal function, or modify the interaction between different functional nodes of the basal ganglia.: In this review, the authors sought to discuss contemporary practice, emerging concepts, and unmet needs for the future of gene therapy in PD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2020.1763794DOI Listing

Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial.

Invest New Drugs 2020 May 18. Epub 2020 May 18.

Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.

Osimertinib is a molecularly targeted agent used to treat non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) T790M mutation. However, its efficacy and safety profile when patients have poor performance status (PS) is unknown. Therefore, we conducted an open-label, multi-center, single-arm phase II study to evaluate its efficacy and safety in EGFR T790M mutation-positive NSCLC patients with Eastern Cooperative Oncology Group PS scores of between 2 and 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-020-00943-0DOI Listing